Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Oncology | Pulmonology | Conference News

Back to Journal Articles

AACR: Lengthy Survival in Some Receiving NSCLC Vaccine

Last Updated: April 05, 2012.

 

Long-term follow-up of belagenpumatucel-L study encouraging for stage IIIB/IV disease

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Use of belagenpumatucel-L, a therapeutic vaccine comprised of four tumor growth factor-β2 antisense gene-modified allogeneic non-small-cell lung cancer (NSCLC) cell lines, is associated with encouraging long-term survival for patients with stage IIIB and IV NSCLC, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.

THURSDAY, April 5 (HealthDay News) -- Use of belagenpumatucel-L, a therapeutic vaccine comprised of four tumor growth factor-β2 antisense gene-modified allogeneic non-small-cell lung cancer (NSCLC) cell lines, is associated with encouraging long-term survival for patients with stage IIIB and IV NSCLC, according to a study presented at the annual meeting of the American Association for Cancer Research, held from March 31 to April 4 in Chicago.

Lyudmila Bazhenova, M.D., from the San Diego Moores Cancer Center in La Jolla, Calif., and colleagues conducted a long-term follow-up of a phase II trial of belagenpumatucel-L. The clinical trial enrolled 75 patients, two with stage II, 12 stage IIIA, 15 stage IIIB, and 46 with stage IV NSCLC, who were randomly allocated into three dose cohorts (1.25, 2.5, or 5 × 107 cells/injection). Patients were followed for a median of 14.5 months, and those with stable disease were followed for 44 months.

The researchers found that the one-, two-, and five-year survival rates were 55, 35, and 20 percent, respectively, with median survival of 14.5 months. Patients with stage IIIB and IV NSCLC enrolled into the second and third dose cohorts had one-, two-, and five-year survival rates of 61, 41, and 18 percent, respectively, with median survival of 15.9 months. Stage IIIB and IV patients with nonprogressive disease following frontline chemotherapy had a median survival of 44.4 months and five-year survival of 50 percent, whereas those who progressed had median survival of 14.1 months and five-year survival of 9.1 percent.

"Based on these data, we have instituted an international, randomized, pivotal Phase III trial to evaluate the efficacy of belagenpumatucel-L in a maintenance setting in stage III/IV NSCLC patients," the authors write.

The study was sponsored by NovaRx Corporation, the manufacturer of belagenpumatucel-L (Lucanix); several authors are employees of NovaRx.

Abstract No. 5367
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Exercise Training Improves Cardiac Parameters in Lupus Next: Studies Investigate Role of De Novo Mutations in Autism

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.